In 2024, there were a total of 285 cases of measles in the United States, with 120 of these cases among children aged under five years. From January 1 to April 3, 2025, there were 607 cases of measles. There were also two reported deaths from the disease during this time, the first since 2015. Measles is a highly contagious disease that can be especially dangerous for young children. Vaccines against measles resulted in a significant decrease in cases in the United States over the last few decades; however, increasing vaccine hesitancy and skepticism has been blamed for recent outbreaks.
In 2023, there were a total of 58 cases of measles in the United States. Around 72 percent of measles cases that year were attributed to unvaccinated individuals. Meanwhile, those with two doses of vaccination only accounted for just three percent of cases. This statistic shows the number of measles cases reported in the United States from 2020 to 2024, by vaccination status.
There were 285 new cases of measles in the U.S. in 2024. Measles, also known as rubeola, is an infectious disease that is highly contagious and affects mostly children. Common symptoms of measles include fever, runny nose, sore throat, cough, and a rash. Although death rates from measles have decreased around the world, it is still responsible for around 81,000 deaths worldwide per year. Measles vaccination The main reason for the decrease in measles cases and deaths is due to high vaccination rates. The widely used MMR vaccine protects against measles, mumps, and rubella and is safe and effective. In 2023, around 91 percent of adolescents in the U.S. aged 13 to 17 years had received an MMR vaccination. However, in recent years there has been a rise in measles cases in many parts of the world due to vaccine hesitancy. Vaccine hesitancy Vaccine hesitancy refers to a refusal or reluctance to have children vaccinated, despite the overwhelming evidence that vaccines are safe and effective. This hesitancy comes from a misunderstanding of the ingredients in vaccines and how they work, a mistrust of doctors and pharmaceutical companies, and belief in the unfounded associations of vaccines with other diseases and disorders.
In 2023, there were around 58 measles cases in the United States, with 20 of these cases among those aged 5 to 19 years. This statistic shows the number of measles cases reported in the United States from 2020 to 2024, by age.
Attribution-NonCommercial 4.0 (CC BY-NC 4.0)https://creativecommons.org/licenses/by-nc/4.0/
License information was derived automatically
Forecast: Number of Reported Measles Cases in the US 2024 - 2028 Discover more data with ReportLinker!
In 2024, there were 285 measles cases in the United States. That year, Minnesota had the highest number of cases, followed by Illinois, and Oregon. Measles is a highly contagious disease that can be especially dangerous for young children. Vaccines against measles resulted in a significant decrease in cases in the United States over the last few decades; however, increasing vaccine hesitancy and skepticism has been blamed for recent outbreaks.
In 1970, there were 22.79 new cases of measles per 100,000 population in the United States. However, this rate dropped to .08 in the year 2024. This statistic shows the number of new cases of measles per 100,000 population in the United States from 1919 to 2024.
Attribution-NonCommercial 4.0 (CC BY-NC 4.0)https://creativecommons.org/licenses/by-nc/4.0/
License information was derived automatically
Forecast: Measles Incidence in the US 2024 - 2028 Discover more data with ReportLinker!
In 2024, there were a total of 285 cases of measles in the United States. Around 40 percent of these cases were hospitalized for isolation or for management of measles complications. From January 1 to April 3, 2025, there were 607 cases of measles, with 12 percent needing hospitalization. Measles is a highly contagious disease that can be especially dangerous for young children. Vaccines against measles resulted in a significant decrease in cases in the United States over the last few decades; however, increasing vaccine hesitancy and skepticism has been blamed for recent outbreaks.
In 2024, there were a total of 285 cases of measles in the United States. Around 89 percent of these cases were among those who were unvaccinated or whose vaccination status was unknown. From January 1 to April 3, 2025, there were 607 cases of measles, with those who were unvaccinated or with an unknown vaccination status accounting for 97 percent of these cases. Measles is a highly contagious disease that can be especially dangerous for young children. Vaccines against measles resulted in a significant decrease in cases in the United States over the last few decades; however, increasing vaccine hesitancy and skepticism has been blamed for recent outbreaks.
In 2024, there were a total of 285 cases of measles in the United States. That year, around half of measles cases among children aged under five years were hospitalized for isolation or for management of measles complications. From January 1 to April 3, 2025, there were 607 cases of measles, with 21 percent of cases among children under five needing hospitalization. Measles is a highly contagious disease that can be especially dangerous for young children. Vaccines against measles resulted in a significant decrease in cases in the United States over the last few decades; however, increasing vaccine hesitancy and skepticism has been blamed for recent outbreaks.
https://www.marketresearchforecast.com/privacy-policyhttps://www.marketresearchforecast.com/privacy-policy
The global measles vaccine market is a significant sector within the broader pharmaceutical landscape, characterized by substantial growth driven by increasing vaccination campaigns and heightened awareness of the disease's potential severity. The market size in 2025 is estimated at $5 billion, reflecting a robust Compound Annual Growth Rate (CAGR) of approximately 7% from 2019 to 2024. This expansion is fueled by several key factors. Firstly, global initiatives aimed at eradicating measles, spearheaded by organizations like the World Health Organization (WHO), have significantly increased vaccination rates in many developing nations. Secondly, a rising incidence of measles outbreaks in certain regions highlights the persistent threat of the disease and necessitates sustained vaccination efforts. Thirdly, advancements in vaccine technology, leading to improved efficacy and safety profiles, contribute to increased market demand. However, challenges remain. Vaccine hesitancy and misinformation pose significant hurdles to achieving complete measles eradication. Furthermore, logistical constraints, particularly in resource-limited settings, impede effective vaccine distribution and administration. Segmentation within the market is primarily driven by application, with hospitals and clinics representing the largest consumer base. Major players like Novartis, Abbott, Johnson & Johnson, Sanofi, and Merck dominate the market, leveraging their extensive distribution networks and research capabilities. Regional analysis reveals North America and Europe as mature markets with high per capita consumption, while significant growth opportunities exist in Asia-Pacific and other developing regions. The forecast period (2025-2033) anticipates continued growth, albeit potentially at a slightly moderated CAGR, as the global vaccination rate progressively improves, but challenges related to vaccine hesitancy and equitable access remain a factor. The projected market expansion hinges on the continued success of global vaccination initiatives and the ability to overcome existing barriers to access. The market's geographical distribution reflects global health disparities. While developed regions maintain high vaccination coverage, significant investments are required in developing nations to enhance cold-chain infrastructure and public health campaigns. Furthermore, future market dynamics will be shaped by advancements in vaccine technology, potentially leading to multi-dose formulations or novel delivery systems. Competition among pharmaceutical companies will remain intense, driving innovation and pricing strategies. Long-term market success will depend on the strategic partnerships between governments, international organizations, and pharmaceutical companies to guarantee widespread and equitable access to measles vaccines.
A survey of adults in the United States from 2024 found that almost 20 percent thought it was definitely true or probably true that getting the measles vaccine is more dangerous than becoming infected with measles. However, this statement is false. Measles is a highly contagious disease that is especially dangerous for children. Vaccinations against measles are safe and effective and have resulted in a significant decrease in measles cases and deaths in the United States. Vaccine hesitancy and skepticism have been blamed for an increasing number of measles outbreaks lately.
https://www.wiseguyreports.com/pages/privacy-policyhttps://www.wiseguyreports.com/pages/privacy-policy
BASE YEAR | 2024 |
HISTORICAL DATA | 2019 - 2024 |
REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
MARKET SIZE 2023 | 3.16(USD Billion) |
MARKET SIZE 2024 | 3.29(USD Billion) |
MARKET SIZE 2032 | 4.5(USD Billion) |
SEGMENTS COVERED | Vaccine Type ,Administration Route ,Patient Population ,Disease Severity ,Vaccine Formulation ,Regional |
COUNTRIES COVERED | North America, Europe, APAC, South America, MEA |
KEY MARKET DYNAMICS | Rising vaccination rates Increased disease prevalence Government initiatives Technological advancements WHO initiatives |
MARKET FORECAST UNITS | USD Billion |
KEY COMPANIES PROFILED | Astellas Pharma Inc. ,Biogen Inc. ,Eli Lilly and Company ,Johnson & Johnson Services, Inc. ,AbbVie Inc. ,Moderna ,Celgene Corporation ,GSK plc ,Pfizer Inc. ,Sanofi S.A. ,Baxter International Inc. ,Merck & Co., Inc. ,Serum Institute of India Pvt. Ltd. ,Amgen Inc. |
MARKET FORECAST PERIOD | 2025 - 2032 |
KEY MARKET OPPORTUNITIES | Increasing global immunization programs Rising incidence of measles outbreaks Government initiatives for vaccination drives Advancements in freezedrying technologies Growing demand for combination vaccines |
COMPOUND ANNUAL GROWTH RATE (CAGR) | 4.01% (2025 - 2032) |
https://www.wiseguyreports.com/pages/privacy-policyhttps://www.wiseguyreports.com/pages/privacy-policy
BASE YEAR | 2024 |
HISTORICAL DATA | 2019 - 2024 |
REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
MARKET SIZE 2023 | 1.67(USD Billion) |
MARKET SIZE 2024 | 1.75(USD Billion) |
MARKET SIZE 2032 | 2.5(USD Billion) |
SEGMENTS COVERED | Drug Class ,Route of Administration ,Disease Stage ,Chemotherapy Regimen ,Patient Population ,Regional |
COUNTRIES COVERED | North America, Europe, APAC, South America, MEA |
KEY MARKET DYNAMICS | Rising cancer prevalence Technological advancements Development of novel therapies Increasing demand for personalized medicine Adoption of targeted therapies |
MARKET FORECAST UNITS | USD Billion |
KEY COMPANIES PROFILED | Oncovation Pharmaceuticals ,Novartis AG ,Daiichi Sankyo Company, Limited ,Axsome Therapeutics ,Sanofi SA ,Aprecia Pharmaceuticals LLC ,Protagonist Therapeutics ,Helsinn Healthcare SA ,Aprea Therapeutics ,Teva Pharmaceutical Industries Ltd. ,Zogenix, Inc. ,Strativa Pharmaceuticals ,Arsia Therapeutics ,Symphogen AG ,Eisai Co., Ltd. |
MARKET FORECAST PERIOD | 2025 - 2032 |
KEY MARKET OPPORTUNITIES | Novel drug delivery systems Targeted therapies Improved patient care Rise in cancer incidence Personalized treatment plans |
COMPOUND ANNUAL GROWTH RATE (CAGR) | 4.56% (2025 - 2032) |
A survey of adults in the United States from 2024 found that 23 percent of Republicans thought it was definitely true or probably true that getting the measles vaccine is more dangerous than becoming infected with measles. However, this statement is false. Measles is a highly contagious disease that is especially dangerous for children. Vaccinations against measles are safe and effective and have resulted in a significant decrease in measles cases and deaths in the United States. Vaccine hesitancy and skepticism have been blamed for an increasing number of measles outbreaks in recent years.
https://www.wiseguyreports.com/pages/privacy-policyhttps://www.wiseguyreports.com/pages/privacy-policy
BASE YEAR | 2024 |
HISTORICAL DATA | 2019 - 2024 |
REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
MARKET SIZE 2023 | 6.5(USD Billion) |
MARKET SIZE 2024 | 6.98(USD Billion) |
MARKET SIZE 2032 | 12.3(USD Billion) |
SEGMENTS COVERED | Vaccine Type ,Application ,Route of Administration ,End User ,Regional |
COUNTRIES COVERED | North America, Europe, APAC, South America, MEA |
KEY MARKET DYNAMICS | Increasing burden of infectious diseases Advancements in biotechnology Growing demand for personalized vaccines Government initiatives and funding Expansion of vaccination programs |
MARKET FORECAST UNITS | USD Billion |
KEY COMPANIES PROFILED | Merck ,Serum Institute of India ,Takeda Pharmaceutical Company ,AstraZeneca ,Novavax ,Moderna ,GlaxoSmithKline ,Bharat Biotech ,Pfizer ,Sanofi ,Abbott Laboratories ,Emergent BioSolutions ,Johnson & Johnson ,Bayer |
MARKET FORECAST PERIOD | 2025 - 2032 |
KEY MARKET OPPORTUNITIES | Increased Global Vaccination Demand Emerging Infectious Diseases Technological Advancements Government Initiatives and Expansion in Developing Regions |
COMPOUND ANNUAL GROWTH RATE (CAGR) | 7.34% (2025 - 2032) |
Rank, number of deaths, percentage of deaths, and age-specific mortality rates for the leading causes of death, by age group and sex, 2000 to most recent year.
https://www.wiseguyreports.com/pages/privacy-policyhttps://www.wiseguyreports.com/pages/privacy-policy
BASE YEAR | 2024 |
HISTORICAL DATA | 2019 - 2024 |
REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
MARKET SIZE 2023 | 3.1(USD Billion) |
MARKET SIZE 2024 | 3.24(USD Billion) |
MARKET SIZE 2032 | 4.6(USD Billion) |
SEGMENTS COVERED | Vaccine Type ,Packaging ,Application ,Age Group ,Distribution Channel ,Regional |
COUNTRIES COVERED | North America, Europe, APAC, South America, MEA |
KEY MARKET DYNAMICS | Rising vaccination rates Increasing government initiatives Growing awareness of disease prevention Technological advancements and Expanding healthcare infrastructure |
MARKET FORECAST UNITS | USD Billion |
KEY COMPANIES PROFILED | GlaxoSmithKline PLC ,Merck & Co. ,Johnson & Johnson ,Serum Institute of India Pvt. Ltd ,Novavax ,SeqirusneweraModerna Therapeutics ,AstraZeneca Plc ,Sanofi Pasteur ,Bavarian Nordic ,Janssen Vaccines ,Takeda Pharmaceutical Company Limited ,BioNTech ,CSL Limited ,Pfizer Inc. |
MARKET FORECAST PERIOD | 2025 - 2032 |
KEY MARKET OPPORTUNITIES | MMR Vaccine Shortage in Asia Pacific Africa Rising Incidence of Measles Cases Globally Government Initiatives for Vaccination Programs Increasing disposable income in developing countries Growing Awareness of Vaccine Importance |
COMPOUND ANNUAL GROWTH RATE (CAGR) | 4.49% (2025 - 2032) |
A survey of U.S. adults from 2024 found that around 73 percent of respondents thought it was very accurate or somewhat accurate that there is no evidence of a link between measles vaccines and getting autism, as stated by the CDC. However, around a quarter of U.S. adults do not accept the CDC's statement that there is no evidence linking the measles vaccine to getting autism. Vaccinations against measles have resulted in significant decreases in cases and deaths from the disease in the United States. However, vaccine hesitancy and skepticism have been blamed for an increasing number of measles cases.
In 2024, there were a total of 285 cases of measles in the United States, with 120 of these cases among children aged under five years. From January 1 to April 3, 2025, there were 607 cases of measles. There were also two reported deaths from the disease during this time, the first since 2015. Measles is a highly contagious disease that can be especially dangerous for young children. Vaccines against measles resulted in a significant decrease in cases in the United States over the last few decades; however, increasing vaccine hesitancy and skepticism has been blamed for recent outbreaks.